AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03778138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib plus Pemetrexed
Description: Anlotinib(12mg QD PO d1-14, 21 days per cycle) plus Pemetrexed (500mg/m2 IV d1)
Study NCT04328701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Cognitive Behavioral Therapy
Description: Mindfulness-based CBT methods are based on pain self-management paradigms, and involve the identification and reduction of maladaptive pain-related cognitions (i.e., catastrophizing), the enhancement of self-efficacy for managing pain, and training in the use of adaptive pain-coping strategies such as relaxation, distraction, and self-talk.
Study NCT02795559 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Inulin
Description: 75g glucose plus 24g inulin dissolved in 300ml water
Study NCT02795559 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Resistant starch
Description: 75g glucose plus 28g resistant starch in 300ml water
Study NCT03903627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: verbal instruction
Description: Verbal instruction for pelvic floor contraction will be given to participants. Ultrasound examination will be conducted to asses urinary bladder displacement being a marker for pelvic floor muscle function.
Study NCT00297037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pimecrolimus 1% cream
Description: pimecrolimus cream or matching placebo BID for 6 weeks
Study NCT00297037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pimecrolimus 1% cream
Description: pimecrolimus cream or matching placebo BID for 6 weeks
Study NCT00581776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Administered by IV at 1.3 mg/m2 days 1 and 4 of each 21 day cycle.
Study NCT00581776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered by IV 375 mg/m2 IV day 1 of each cycle during induction chemotherapy, then weekly for four weeks during consolidation therapy; and then once every 12 weeks for up to 5 years (or until disease progression).
Study NCT00581776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered by IV at 300 mg/m2, 6 doses spaced 12 hours apart on days 1-3 of each cycle, to start after completion of rituximab infusion
Study NCT02376023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth
Description: Text and voice messages sent to study participants reminding them to schedule a PAP smear.
Study NCT00581776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given as a continuous infusion, 50 mg/m2 over 48 hours days 1-2 of each cycle, to start after completion of rituximab infusion.
Study NCT00581776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1 mg administered by IV on day 3 of each cycle.
Study NCT00581776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg orally on days 1-4 of each cycle.
Study NCT04922918 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ligilactobacillus salivarius MP101
Description: Administration of the strain through a fermented milk
Study NCT03503903 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wet Cupping
Description: CT was applied using plastic disposable vacuum cups on the back in the 5 areas of C7 cervical spine (DU14 acupoint), T2-4 lateral spine bilaterally (BL41-42 acupoint) and T6-8 lateral spine bilaterally (BL44-46), which are the recommended sites for headache (12). The cupping technique procedure was conducted in five phases:Primary suction,Area disinfection,Scarification,Secondary suction and bloodletting,Removing and dressing.
Study NCT02327858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive text messages
Description: Patients in all the intervention groups will receive twice daily supportive SMS text messages for 3 months. The messages will be tailored towards improving mood, compliance with medication or targeting abstinence from alcohol in accordance with the primary aims of our study. As far as possible, the majority of the text messages will reflect lessons patients usually learn during CBT and addiction counselling sessions.
Study NCT04471636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Withings ScanWatch
Description: The smart watch is capable of recording SpO2, ECG, and heart rate.
Study NCT02523846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Description: Investigators use the formula that was published by Pamela Macintyre in her paper entitled Age is the Best Predictor of Postoperative Morphine Requirements. The estimation for the first 24-hour morphine requirement after surgery is calculated as: 100 - age (year).~So, half of the total 24-hour morphine requirement will be infused over 24 hours.~e.g. background morphine infusion= (100-Age)/ 2/ 24 (mg/hour)
Study NCT02523846 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient re-education
Description: A similar leaflet will be used to re-educate patient at 4 hour after surgery. The correct method to initiate IV-PCA dose, possible side effects and addiction issue will be explained again and re-emphasized
Study NCT02523846 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient re-education
Description: A similar leaflet will be used to re-educate patient at 4 hour after surgery. The correct method to initiate IV-PCA dose, possible side effects and addiction issue will be explained again and re-emphasized
Study NCT04582955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide in combination with chemotherapy
Description: Chidamide, orally,20mg at day 0,4,7,11,21,every 3 weeks; in combination with Docetaxel 75mg/m2,intravenous infusion，at day1 every 3 weeks，and Epirubicin 75mg/m2, intravenous infusion，at day1 every 3 weeks
Study NCT02929459 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Riboflavin Dose 1
Study NCT02929459 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Riboflavin Dose 2
Study NCT02929459 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04378114 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter. C sensor algorithm applied retrospectively to raw sensor data.
Description: Characterize the impact of acetaminophen ingestion on the accuracy of Guardian™ Sensor (3) when C sensor algorithm is used.
Study NCT04378114 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter. Zeus sensor algorithm applied retrospectively to raw sensor data.
Description: Characterize the impact of acetaminophen ingestion on the accuracy of Guardian™ Sensor (3) when Zeus sensor algorithm is used.
Study NCT04378114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetominophen
Description: One time administration of acetaminophen.
Study NCT01832532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: daily use of drug. Titrated up from 0.6mg/day to 1.8mg/day or highest tolerated dose
Study NCT03057652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReWalk
Description: ReWalk is a type of wearable robotic exoskeleton (WRE). Subjects will be randomly assigned the order of participation in the exoskeleton devices.~ReWalk training sessions will be scheduled for one hour to include don/doff of device, sit to stand, standing balance and walking. ReWalk phase will require 2 hours pre and 2 hours post training for outcome measurement assessments, plus a minimum of 5 training sessions, with the possibility of up to 15 training sessions to reach a minimal assistance level. The total time commitment for each subject will range from 14-20 weeks and cover 27-72 hours.
Study NCT03020030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erwinia asparaginase
Description: Only for patients with Pegaspargase allergy or silent inactivation.
Study NCT02208830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulmonary rehabilitation
Description: Pulmonary rehabilitation: 8 week, twice weekly exercise program with aerobic treadmill training and lower limb strength training.
Study NCT03020030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinia asparaginase
Description: Only for patients with Pegaspargase allergy or silent inactivation.
Study NCT03020030 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: Standard of Care
Study NCT03057652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EKSO
Description: EKSO is a type of wearable robotic exoskeleton (WRE). Subjects will be randomly assigned the order of participation in the exoskeleton devices.~EKSO training sessions will be scheduled for one hour to include don/doff of device, sit to stand, standing balance and walking. EKSO phase will require 2 hours pre and 2 hours post training for outcome measurement assessments, plus a minimum of 5 training sessions, with the possibility of up to 15 training sessions to reach a minimal assistance level. The total time commitment for each subject will range from 14-20 weeks and cover 27-72 hours.
Study NCT03020030 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CYTARABINE
Description: Standard of Care
Study NCT02208830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional program
Description: The conventional program is conducted with duration of 8 week, twice weekly. The techniques used will be: expiration with the glottis open in lateral posture (Eltgol), autogenous drainage (AD) and shaker. Each technique will last for 30 minutes.
Study NCT02396719 — intervention group
Intervention type: DEVICE
Intervention: LenSx® Laser
Description: Used for cornea incision, capsulotomy and lens fragmentation during cataract surgery
Study NCT02121652 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia
Description: Cognitive behavioral therapy for insomnia includes content on sleep restriction, stimulus control, relaxation, cognitive restructuring and sleep hygiene content delivered in a 90 minute group intervention with two follow up phone calls.
Study NCT02121652 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy eating control
Description: Healthy eating control involves healthy eating content delivered in a 90 minute group session with two follow up phone calls.
Study NCT00770328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: 400mg PO TID x 8 weeks
Study NCT00770328 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PO TID x 8 weeks
Study NCT02881697 — intervention group
Intervention type: OTHER
Intervention: Adipose tissue sampling
Study NCT04289363 — intervention group
Intervention type: BEHAVIORAL
Intervention: Clinical program implementation
Description: Using mixed methods and triangulating multiple sources of data collected over the course of parent and ancillary studies to evaluate the feasibility, acceptability, sustainability, and impact of the ED-initiated BUP clinical program and implementation facilitation strategy and identify factors influencing diffusion and effectiveness. Converging provider and patient perspectives and field notes with process measures and intervention outcomes, including proportions screened, treated, and engaged in treatment, will provide explanation to contextualize and better understand feasibility, acceptability, and factors associated with the rate with which the ED-initiated BUP innovation is adopted and how well it is sustained.
Study NCT03020030 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DASATINIB
Description: Standard of Care
Study NCT03020030 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DEXAMETHASONE
Description: Standard of Care
Study NCT00578175 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Priorix-Tetra™ (MMRV vaccine 208136)
Description: One subcutaneous injection.
Study NCT01998763 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules have similar appearance and smell as 400 IU vitamin D3 capsules,
Study NCT01998763 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 2000 IU per day
Study NCT03714243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate BBBD
Description: Using ExAblate Model 4000 Type-2 to temporarily disrupt the blood brain barrier in patients with Her-2 positive breast cancer and brain metastases
Study NCT00578175 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ProQuad®
Description: One subcutaneous injection.
Study NCT00578175 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix®
Description: Two intramuscular injections.
Study NCT00578175 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix®
Description: Two intramuscular injections.
Study NCT00578175 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar®
Description: One intramuscular injection.
Study NCT00578175 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar®
Description: One intramuscular injection.
Study NCT02761707 — intervention group
Intervention type: OTHER
Intervention: Electrical Brainstem Responses
Description: Eye blink responses will be induced using standard stimulating electrodes employed in surface electromyography (EMG). The subjects will recline with their eyes gently closed. Sticky electrodes will be placed to the left and below the left eye. 6 different facial regions will be stimulated. The electrical stimulation will be kept constant during the test sessions. To prevent habituation, the stimuli will be delivered randomly at intervals of 45-60 sec. Four 0.2 msec pulses will be presented. In some cases, paired pulse stimulation will be performed, and a conditioning stimulus will be applied to the target facial regions at the following intervals: 10, 200, 400, 600 and 800 msec. 4 pulses will be presented at each stimulus interval with randomized interval and pulse sequences.
Study NCT02761707 — intervention group
Intervention type: OTHER
Intervention: Olfactory Tests
Description: Olfactory testing will be performed using standard tests. The University of Pennsylvania Smell Identification Test (UPSIT) assesses a subjects ability to identify odors in a forced choice format. The Snap and Sniff Threshold Test provides a threshold measure of phenyl ethyl alcohol. Short-term odor memory will be assessed using a standardized 12-item four-alternative forced-choice Odor Memory Test. This non-lexical test employs 10-, 30-, and 60-second delay intervals between the presentation of the target odorant and the first of four successively presented odors from which the target is to be selected.
Study NCT02761707 — intervention group
Intervention type: OTHER
Intervention: Visual Deprivation
Description: During a 2-hour visual deprivation period, subjects will wear comfortable light-tight goggles with lenses that have been blackened by flat black paint. Subjects will be given the opportunity to recline comfortable in a padded reclining chair during this time.
Study NCT02761707 — intervention group
Intervention type: OTHER
Intervention: Peripheral Nerve Stimulation
Description: Electrical stimulation will be applied to a nerve of your arm. Sticky electrode pads will also be placed on a hand muscle. You will receive electrical stimulations that lasts less than a second. The stimulations will make your muscle twitch.
Study NCT03057652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REX
Description: REX is a type of wearable robotic exoskeleton (WRE). Subjects will be randomly assigned the order of participation in the exoskeleton devices.~REX training sessions will be scheduled for one hour to include don/doff of device, sit to stand, standing balance and walking. REX phase will require 2 hours pre and 2 hours post training for outcome measurement assessments, plus a minimum of 5 training sessions, with the possibility of up to 15 training sessions to reach a minimal assistance level. The total time commitment for each subject will range from 14-20 weeks and cover 27-72 hours.
Study NCT02425514 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervios ChronOs
Description: The ACDF surgery will be carried out with Cervios ChronOs after randomization procedure.
Study NCT02425514 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoMax™
Description: The ACDF surgery will be carried out with NovoMax™ after randomization procedure.
Study NCT04611802 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)
Description: Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21 in Initial Vaccination Period.
Study NCT04611802 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Initial Vaccination Period)
Description: Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21 in Initial Vaccination Period.
Study NCT04611802 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period)
Description: In Crossover Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0 or Day 21
Study NCT04611802 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Crossover Vaccination period)
Description: In Crossover Vaccination period, one dose of intramuscular (deltoid) injection of placebo (0.5 mL) on Day 0 or Day 21
Study NCT04611802 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)
Description: In Booster Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0
Study NCT04611802 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)
Description: In Second Booster Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0
Study NCT00461279 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavior Therapy
Description: Reframing and understanding cognitions of depression
Study NCT00461279 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interpersonal Psychotherapy
Description: Established psychotherapy for depression
Study NCT03846284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.
Study NCT03846284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.
Study NCT03846284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 50mg
Description: caudal block with bupivacaine 0.25% 1mg/kg plus Magnesium sulfate 50 mg diluted in 10 cm saline.
Study NCT03846284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 30 mg
Description: caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.~+ I.V injection of Magnesium sulfate 30mg/kg diluted in 10 cm saline over 10 mins then, fol I.V infusion one ampule of Magnesium sulfate 500mg diluted in 50 cm saline with rate 10 mg/kg/h.
Study NCT03875352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CHG technique
Description: The CHG technique includes treatment using dressing with chlorhexidine.
Study NCT03875352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HMG technique
Description: The HMG technique includes treatment using hydrophilic methacrylate gel and transparent foil.
Study NCT01378468 — intervention group
Intervention type: OTHER
Intervention: oral triglyceride tolerance test (not a therapeutic intervention as such but a new diagnostic test)
Description: see Ebinger et al., IJS, 2010
Study NCT04070612 — intervention group
Intervention type: OTHER
Intervention: Blood sample
Description: A blood sample of 2 times 2 to 5 ml additional maximum
Study NCT01229722 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Beeper
Description: Beepers are handheld portable devices which can be attached to a belt. At regular intervals corresponding to the participant's preferred reminder time, they buzz for a few minutes or until the participant presses a button to stop the buzzing.
Study NCT03635242 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control. no therapeutic program
Description: The control group continued to perform their daily activities without changing any habit. Group of healthy subjects Assessment of postural control through accelerometry and pressure platform
Study NCT01229722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARemind
Description: ARemind will personalize reminder messages based on adherence levels and facilitate patient phone calls with social workers/adherence counselors when appropriate. It will also consist of a text-messaging or interactive voice response (IVR) or phone-based pill count remote adherence assessment module.
Study NCT02116088 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Teacher Coaching
Study NCT01716780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Patients allocated to the intervention group will undergo prospective, proactive, integrated, structured pain treatment according to recent guidelines on cancer pain care
Study NCT02406105 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiosurgical thalamotomy
Description: Cybernetic microradiosurgery based thalamotomy
Study NCT02406105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CyberKnife